A Navy physician who spent his early career fighting HIV never planned to upend cancer treatment. Carl June, born in Washington, D.C., in 1953, earned his medical degree from the Uniformed Services University of the Health Sciences in 1979. As a U.S. Navy doctor, he studied HIV, an experience that equipped him with the tools to later engineer immune cells to attack malignancies.
Today he directs the Center for Cellular Immunotherapies at the University of Pennsylvania’s Perelman School of Medicine. June’s laboratory published results from the first successful CAR-T clinical trial in 2010, a milestone that reshaped oncology.
Three patients with chronic lymphocytic leukemia received the experimental therapy. Two achieved remission, and one of those patients remained cancer-free for more than a decade.
From HIV Research to a Living Drug
CAR-T therapy represents a form of immunotherapy that engineers a patient’s own immune cells to recognize and destroy cancer. The approach emerged from earlier cellular adoptive immunotherapies.
Researchers at the National Institutes of Health had studied tumor-infiltrating lymphocytes — T cells that naturally enter a tumor. Doctors learned to isolate these cells from resected tumors and expand them in a laboratory. This method proved effective for treating metastatic melanoma, a highly immunogenic cancer.
Yet medical challenges remained. Some T cells failed to stay active or lacked sufficient numbers to stop disease progression.
Other treatments, such as targeted therapy and immune checkpoint blockade, also left some patients without a viable option. June’s work built on those gaps. Drawing on his HIV research background, he developed techniques to engineer T cells to better recognize and attack malignant growths.
The therapy shifted medicine toward a personalized approach, using a patient’s own biology to fight diseases that resist standard care. For patients who do not respond to traditional oncology treatments, CAR-T offers a potential alternative.
The 2010 clinical trial marked a turning point. With the publication of those results, the calculus for oncologists around the world changed. The proof that engineered cells could induce long-term remission in blood cancer patients opened a new front in the war on leukemia.
Pediatric Patient and FDA Approval
In 2012, June’s team treated Emily Whitehead, the first pediatric patient to receive CAR-T therapy. Her case captured public attention and accelerated the timeline for regulatory approval. In 2017, the U.S. Food and Drug Administration approved Kymriah, the first CAR-T therapy developed from June’s research.
The decision represented a turning point in cancer treatment: a living drug, engineered from a patient’s own immune cells, now had the federal government’s backing. June has published more than 400 peer-reviewed papers and holds numerous patents.
The scientific establishment has recognized his contributions. He received the 2020 Wolf Prize in Medicine, sharing the award with Zelig Eshhar and Steven Rosenberg. In 2024, he added the Breakthrough Prize in Life Sciences to his list of honors.
The Next Frontier: CRISPR and Access
As of 2024, June’s laboratory continues developing next-generation CAR-T therapies, including those using CRISPR gene-editing technology. Combining cellular therapy with precise genetic engineering could expand treatment options beyond blood cancers to solid tumors, an area where current CAR-T approaches have limited effectiveness.
The integration of CRISPR may help overcome the barriers that have so far prevented engineered T cells from tackling many common solid malignancies. June has also been a vocal advocate for making CAR-T therapy more affordable and accessible. The current cost of treatment remains a barrier for many patients, limiting who can benefit from a therapy that represents a paradigm shift in oncology.
While the science continues to advance, the challenge of delivering this personalized medicine to a broader population remains unresolved. Consult your doctor for medical advice.
